EP344/#697 Preliminary characterisation of circulating human papillomavirus 16/18/31/35 antibodies for the detection of cervical neoplasia by a rapid point of care test

Abstract

the ORR was 54%. Of patients with Stage III/IV disease the median PFS was 5.7 months. Among those with paired biopsies, there was no change in H-score pSMAD after C1 in 3/4 patients with a partial response. 4 patients with paired samples had a decrease in epithelial component, this did not correlate with response. Conclusions GB was well tolerated with TC with no DLTs. Paired biopsies were too limited to make conclusions. However, the putative mechanism of action of galunisertib and the well tolerated nature of the combination would warrant further exploration.